Melinta Therapeutics’ Baxdela™ to be Featured in Six Poster Presentations at IDWeek 2016™
October 26, 2016 08:00 ET
|
Melinta Therapeutics
NEW ORLEANS, Oct. 26, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company exclusively focused on developing novel antibiotics to treat serious bacterial infections,...
Melinta Therapeutics Submits Baxdela New Drug Application for Hospital-Treated Skin Infections
October 24, 2016 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that it has...
Cempra to Present at Three Upcoming Investor Conferences
September 01, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin at FDA Antimicrobial Drugs Advisory Committee Meeting on November 4, 2016
August 30, 2016 09:15 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra’s Pivotal Phase 3 SOLITAIRE-IV Study of IV to Oral Solithromycin Published in Clinical Infectious Diseases
August 25, 2016 16:05 ET
|
Cempra, Inc.
— Both pivotal Phase 3 studies now published in leading infectious disease journals — — FDA and EMA currently reviewing marketing applications for solithromycin for CABP in U.S. and EU — CHAPEL...
Cempra Announces European Medicines Agency Validates MAA for Solithromycin for Treatment of CABP
August 23, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 23, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Appoints Dr. David Zaccardelli to Board of Directors
August 11, 2016 16:05 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra Reports Second Quarter 2016 Financial Results and Provides Corporate Update
August 01, 2016 16:05 ET
|
Cempra, Inc.
Current cash balance now expected to fund operations through 2017 Management to host webcast and conference call today at 4:30 p.m. EDTCHAPEL HILL, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- ...
Cempra Appoints John Bluth Executive Vice President, Investor Relations and Corporate Communications
August 01, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Report Second Quarter 2016 Financial Results
July 25, 2016 07:30 ET
|
Cempra, Inc.
CHAPEL HILL, N.C., July 25, 2016 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...